Natallia Abramovich
Internal Medicine · Seneca, SCNPI 1568647949
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 261 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $968, 2.3 times the $424 reported in 2019.
Across 261 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$821
- Lilly USA, LLC$630
- AbbVie$555
- GSK$440
- Pfizer$316
- AstraZeneca$295
- plus $1K from 24 others
What the payments were for
- Food & beverage$4,32299%
- Education$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 54 | $821 |
| Lilly USA, LLC | 35 | $630 |
| AbbVie(2 entities) | 28 | $555 |
| GSK | 31 | $440 |
| Pfizer | 21 | $316 |
| AstraZeneca | 16 | $295 |
| Bayer | 11 | $178 |
| Merck | 4 | $114 |
| Sanofi-aventis U.S. LLC | 5 | $90 |
| Novartis | 6 | $88 |
| Dexcom, Inc. | 5 | $83 |
| Abbott | 5 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $81 |
| Neurocrine Biosciences, Inc. | 4 | $77 |
| Exact Sciences | 5 | $73 |
| Johnson & Johnson | 5 | $69 |
| Boehringer Ingelheim | 5 | $66 |
| Astellas Pharma US Inc | 3 | $48 |
| Amgen | 2 | $32 |
| Nestle Healthcare Nutrition Inc. | 2 | $31 |
| Sunovion Pharmaceuticals Inc. | 2 | $27 |
| Eisai Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Boston Scientific | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$107
How this compares
$4,361 in reported general payments places this provider in the 85th percentile of 1,498 internal medicine providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 158 | $166,456 |
| JardianceEmpagliflozin | 102 | $143,677 |
| MounjaroTirzepatide | 69 | $117,788 |
| OzempicSemaglutide | 54 | $102,396 |
| TrulicityDulaglutide | 54 | $98,476 |
| FarxigaDapagliflozin Propanediol | 76 | $86,717 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $54,026 |
| RybelsusSemaglutide | 18 | $41,082 |
| XareltoRivaroxaban | 15 | $24,461 |
| Nurtec OdtRimegepant Sulfate | 22 | $21,625 |
| MyrbetriqMirabegron | 25 | $18,809 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $13,453 |
| Repatha SureclickEvolocumab | 11 | $9,394 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $7,388 |
| Gabapentin | 285 | $6,387 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $630 | $216,264123 claims |
| PfizerEliquis, Nurtec Odt | $316 | $188,081180 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $66 | $151,065113 claims |
| Novo NordiskOzempic, Rybelsus | $821 | $143,47872 claims |
| AstraZenecaFarxiga, Symbicort, Nexium | $295 | $93,654100 claims |
| GSKTrelegy Ellipta | $440 | $54,02666 claims |
| Johnson & JohnsonXarelto | $69 | $24,46115 claims |
| Astellas Pharma US IncMyrbetriq | $48 | $18,80925 claims |
| AbbVieSynthroid | $555 | $2,26946 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Seneca
- Jerry BackNorth Charleston$322K
- Jan BasileCharleston$278K
- Mark PurcellGreenville$165K
- John CleekCharleston$136K
- William BunnHilton Head Island$125K
- Zion LammGreenville$118K
- Bruce GrayGreenville$111K
- Leonard AlsfeldCharleston$91K
- Edward Botse-BaidooMyrtle Beach$90K
- Lisa DarbyGreenville$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.